ABSTRACT
Protein tyrosine phosphatase H-type receptor (PTPRH) gene encodes a gastric cancer associated protein, which exerts its biological function through tyrosine phosphorylation in the post-translational COOH- terminal region. PTPRH is abnormally expressed in a variety of tumors, and its biological function is closely related to the occurrence, development and prognosis of tumors.
Subject(s)
Humans , Phosphorylation , Protein Tyrosine Phosphatases , Proteins , Stomach Neoplasms , TyrosineABSTRACT
Objective: To study the factors affecting the survival and prognosis of patients with intracranial ependymoma. Methods:From January 2008 to January 2018, the prognoses of 276 patients with intracranial ependymoma were analyzed using Log-rank and Cox model analysis. The variables included sex, age, tumor location, tumor diameter, resection extent, pathological grade, Ki-67 index, postoperative radiotherapy, and postoperative chemotherapy. Results: Tumor location, resection extent, and postoperative radiothera-py could all affect the overall survival (OS) and progression-free survival (PFS) of patients with intracranial ependymoma (P<0.001) and independently affected the OS (P<0.001, P<0.001, and P=0.002, respectively) and PFS (P<0.001, P<0.001, and P=0.001, respectively). The Ki-67 index was an independent factor affecting PFS in patients with intracranial ependymoma (P<0.001). The supratentorial loca-tion and Ki-67 index≥10% were independent risk factors indicating poor prognosis (P<0.001). Total resection and postoperative radio-therapy were protective factors (P<0.001 and P=0.001, respectively). Conclusions: Tumor location, resection extent, Ki-67 index, and postoperative radiotherapy are independent factors affecting the prognosis of intracranial ependymoma. It is helpful to extend the PFS and OS of patients through complete tumor resection or postoperative radiotherapy.
ABSTRACT
Objective The objective of this study was to investigate the relationship between serum long-chain non-cod-ing RNA MALAT1 and AFAP1-AS1 and clinicopathological features,and prognosis of nasopharyngeal carcinoma(NPC). Methods A total of 136 patients with nasopharyngeal carcinoma confirmed by pathology in our hospital were selected from April 2013 to June 2015. During the same time,54 outpatients for health examination in our hospital were selected as the control group and nasopharynge-al carcinoma group. Real-time fluorescence reverse transcription analysis was used to analyze the expression of lncRNA MALAT1 and AFP1-AS1. The relationship between the expression of lncRNA MALAT1 and AFP1-AS1,and clinicopathological characteris-tics was analyzed by χ2 test. Log-rank assay was used to analyze serum long-chain non-coding RNA MALAT1 and prognostic differences in patients with different expression levels of AFAP1-AS1. Results Compared with the control group,the serum levels of RNA MALAT1 and RNA AFAP1-AS1 in the nasopharyngeal carcinoma group were significantly increased(P<0. 001);The expres-sions of lncRNA MALAT1 and AFAP1-AS1 was not related to age(P>0. 05);The maximum diameter of the tumor was≥5 cm,the pathological stage was higher,the TNM stage was higher,the deeper in the infiltration depth,the infiltration of lymphatic vessels,the lymph node metastasis,and the recurrence and the higher in high expressive rates of lncRNA MALAT1 and AFAP1 -AS1 ( P <0. 05). The 2-year survival rate and survival time of lncRNA MALAT1 and AFAP1-AS1 in the low expression group were signifi-cantly higher than those of the high expression group(P<0. 001);Multivariate Cox stepwise regression analysis showed that low ex-pression of lncRNA MALAT1(HR=0. 52,95% CI:0. 37~0. 81)and low expression of lncRNA AFAP1-AS1(HR=0. 56,95% CI:0. 51~0. 83)were independent prognostic protective factors for NPC patients(P<0. 001). Conclusion The serum long-chain non-coding RNA MALAT1 and AFAP1-AS1 are elevated in patients with NPC,and are positively correlated with malignant progression of NPC. NPC patients with low expression of lncRNA MALAT1 and AFAP1-AS1 serum have a good prognosis;MALAT1 and AFAP1 -AS1 can be used as new markers for the diagnosis of nasopharyngeal carcinoma.
ABSTRACT
Objective To evaluate the effect of surgery-radiotherapy interval (SRI) on clinical prognosis of locally advanced stage c Ⅱ-Ⅲ breast cancer patients treated with neoadjuvant chemtherapy and modified radical mastectomy.Methods Clinical data of 1 087 breast cancer patients treated with neoadjuvant chemotherapy and modified radical mastectomy from 11 hospitals in China were retrospectively analyzed.The optimal threshold value of SRI upon clinical prognosis was determined by maxstat method.The effect of SRI on clinical prognosis was evaluated by using multivariate Cox regression analysis and propensity score matching (PSM).Results The median follow-up time was 72.9 months.The 5-year disease-free survival (DFS) and overall survival (OS) rates were 68.1% and 81.8%.All patients were divided into SRI ≤18 weeks (n=917) and SRI> 18 weeks groups (n=170).Multivariate Cox regression analysis demonstrated that hormone receptor status (P<0.001),pathological T stage (P<0.001),pathological N stage (P<0.001) and SRI (P=0.023) were independent influencing factors of DFS.Hormone receptor status (P=0.013),pathological T stage (P=0.006),pathological N stage (P<0.001),endocrine therapy (P=0.013) and SRI (P=0.001) were significantly associated with OS.After balancing the clinical and pathological factors with PSM,patients with SRI< 18 weeks had superior DFS and OS to those with SRI> 18 weeks.Conclusions SRI affects the clinical prognosis of locally advanced breast cancer patients treated with neoadjuvant chemotherapy and modified radical mastectomy.Radiotherapy should be performed within 18 weeks after mastectomy.
ABSTRACT
Objective: To evaluate the potential dosimetric beneifts and optimal indications of intensity modulated radiation therapy (IMRT) and hybrid intensity modulated radiation therapy (Hybrid IMRT) for the left side breast cancer patients after breast-conservation therapy. Methods: Eight patients with left breast carcinoma who received breast-conservation surgery were selected for this study. Two plans were designed in 3-dimensional treatment planning system. The dose distributions of target volume and normal tissues, conformal index (CI) and heterogeneous index (HI) were analyzed by dose-volume histogram (DVH). Results: The PTV coverage was the same in the two radiotherapy plans. A better dose uniformity throughout the whole breast in Hybrid IMRT plan was achieved. The CI, the percentage of PTV receiving more than 105% prescribed dose (V105%), the percentage of PTV receiving more than 110% prescribed dose (V110%), and the Dmax, Dmin and Dmean of PTV were similar in the two plans. We compared the Hybrid IMRT with IMRT: V13of the ipsilateral lung decreased from 27.66% to 20.7%, V5 of the contralateral lung decreased from 8.01% to 2.25%, V10 and V20 of the heart decreased from 35.23% and 16.77% to 19.22% and 10.6% respectively, V5 and V10 of the contralateral breast decreased from 35% and 10.39% to 20.38% and 5.7% respectively, all with significant difference. V30 and V40 of the ipsilateral lung and V40 of the heart increased by 1.28%, 1.48%, and 2.48%, with signiifcant difference. Conclusion: Hybrid IMRT is a better choice for patients whose treatment position is inaccurate or cannot be repeated well.
ABSTRACT
OBJECTIVE@#To explore the reversal effect and mechanism of lobeline on the multidrug-resistance (MDR) of human breast cancer cells MCF-7/ADM.@*METHODS@#In human breast cancer cell line MCF-7/ADM, MTT assay was used to determine the cell growth inhibiting ratio of MCF-7/ADM by ADM and Fu. Fluorospectorphotometer was employed to investigate the intracellular concentration of rhodamine123 to reflect the effect of lobeline on the activity of MDR-related protein P-glycoprotein (P-gp). Taking untreated MCF-7/ADM cells as controls, flow cytometry was applied to detect the intracellular concentration of rhodamine123 in MCF-7/ADM cell intervened with lobeline of 20 micromol/L.@*RESULTS@#The sensitivity of MCF-7/ADM to ADM and Fu was significantly increased by lobeline in a dose-dependent manner. The inhibitive concentration 50 (IC(50)) of ADM declined from (44.81+/-0.43) mg/L to (16.72+/-0.75) mg/L with a reversion index of 2.68. The IC(50) of Fu declined from (53.12+/-1.60) mg/L to (38.90+/-1.43) mg/L with a reversion index of 1.37. The fluorescence intensity of lobeline-treated cells was significantly higher than that of the controls, when the concentration of lobeline was more than 10 micromol/L. With fewer side effects, the reversal efficacy of 20 micromol/L lobeline was 71.6% of the classical MDR reversal agent of verapamil at the same concentration.@*CONCLUSION@#Lobeline can reverse the MDR of MCF-7/ADM cells by inhibiting the activity of P-glycoprotein.
Subject(s)
Female , Humans , Breast Neoplasms , Pathology , Cell Line, Tumor , Drug Resistance, Multiple , Drug Resistance, Neoplasm , Glycoproteins , Lobeline , PharmacologyABSTRACT
OBJECTIVE@#To investigate the inhibitive effect of E1A gene carried by PEI-Fe(3)O(4) nanometer particle (NP) on the cell growth of human cervical carcinoma cell in vitro and its mechanism, and to provide the experimental evidence for the feasibility of gene therapy for human cervical carcinoma.@*METHODS@#E1A gene conjugated to PEI-Fe3O4 NP was transfected into human cervical carcinoma cell line Hela. The cell growth curve of Hela was drawn, the doubling time and the number of colony formations on the soft agar were calculated based on the cell count. RT-PCR and Western blot were used to detect the expression of the E1A and HER-2/neu in Hela cells.@*RESULTS@#The cell doubling time of Hela cells transfected with E1A gene (Hela-E1A) was 1.53 times and 1.58 times longer than that of the Hela transfected with blank vector (Hela-vector) and blank Hela control (Hela), respectively. The E1A transfected Hela cells grew slower than those of the control group. The cell colony formation efficiency in the Hela-E1A (6.62%) group was significantly lower than that of Hela (30.48%) and Hela-vector (28.3%) groups (P<0.05). As compared to Hela and Hela-vector, the inhibition rate of Hela-E1A was 78.28% and 76.62% respectively. RT-PCR and Western blot demonstrated that the overexpression of E1A through gene transfection significantly inhibited mRNA and protein expression of HER-2/neu in Hela cells.@*CONCLUSION@#E1A gene can suppress the cell growth of human cervical carcinoma cell Hela in vitro. Down-regulated expression of HER-2/neu gene by E1A overexpression in Hela might contribute to the Hela growth inhibitive effect of E1A.